Transition from parenteral to oral treprostinil in pulmonary arterial hypertension.

  title={Transition from parenteral to oral treprostinil in pulmonary arterial hypertension.},
  author={Murali M. Chakinala and Jeremy P. Feldman and Franz P Rischard and Michael A. Mathier and Meredith Broderick and Nicole Leedom and Kevin Laliberte and Richard J. White},
  journal={The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation},
  volume={36 2},
BACKGROUND Parenteral prostanoids are effective treatment for pulmonary arterial hypertension, but long-term pump infusion systems have significant delivery-related safety and convenience limitations. METHODS Subjects with a favorable risk profile transitioned from parenteral to oral treprostinil using a protocol-driven titration during 5 days of inpatient observation. Baseline and Week 24 assessments included 6-minute walk distance, echocardiogram, right heart catheterization… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-9 of 9 extracted citations


Publications referenced by this paper.
Showing 1-10 of 23 references

A pharmacokinetic and tolerability comparison in subjects transitioning from twice daily to three times daily dosing of oral treprostinil

  • RJ White, K Frutiger, A Theuer
  • Chest 2014146:
  • 2014
1 Excerpt

Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension

  • VA de Jesus Perez, E Rosenzweig, LJ Rubin
  • Am J Cardiol
  • 2012

Similar Papers

Loading similar papers…